Program:
Overview of significant biological aspects presented during the meeting, including:

1. Exploration of somatic mutations in CML (02:36)

• Somatic mutations at diagnosis in patients with CP-CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the International CML Foundation (iCMLf) Genomics Alliance on the HARMONY platform (02:36)
• Distinct patterns of mutant ASXL1 over time and their implications for treatment failure and BCR::ABL1 mutation development in newly diagnosed patients with CML-CP treated with asciminib vs investigator-selected tyrosine kinase inhibitors in the ASC4FIRST study (04:36)
• Molecular landscape and clonal evolution in minor versus major BCR::ABL1 CML under tyrosine kinase inhibition: A study from the French group Fi-LMC (07:08)

2. TFR prediction: from bulk to single-cell analysis (10:13)

• DNA-based MRD monitoring enhances risk stratification during TKI dose reduction in CML: Evidence from a clinical trial (11:47)
• A machine-learning approach identifies a transcriptomic signature predicting treatment-free remission in CML (13:43)
• Single-cell analysis of chronic myeloid leukemia bone marrow at the time of TKI discontinuation reveals stem-cell alterations associated with recurrence versus treatment-free remission (15:35)
• A single-cell atlas of diagnostic bone marrow to uncover the origins of CML relapse following therapy cessation (17:28)
  
  

3. Questions and Answers (Clinical and Biological) (21:58)

If you have any questions or comments to the speaker, please email info@cml-foundation.org.